by Dr. Lisa Offringa, PhD, February 25th 2026
Views No Comments
Glucose Regulation Across the Lifespan: What Changes & Why

Author: Dr. Lisa Offringa, PhD

Blood glucose regulation is a coordinated process involving insulin secretion from pancreatic β-cells, insulin sensitivity in muscle and liver, gut and incretin signals, adipose cytokines, and metabolites from the microbiome. (1–4,8,28,31) Across the lifespan, predictable shifts in these systems create distinct risk windows for insulin resistance and impaired glucose regulation. (1–4,10–12,23–27)

For practitioner brands and clinicians, this demographic framing is clinically useful: it clarifies who is at risk when, why postprandial excursions differ between patients, and how lifestyle plus targeted meal-time interventions can be positioned in care plans.

Table of Contents

  1. Why Blood Sugar Support Looks Different for Everyone
  2. Glucose Metabolism Across the Lifespan
  3. Sex-Based Differences in Blood Sugar and Insulin Sensitivity
  4. Evidence-Based Strategies for Postprandial Control
  5. Targeted Meal-Time Interventions: Premier Glucose Manager with Reducose® + GlucoVantage® Dihydroberberine
  6. Key Takeaways
  7. References

Why Blood Sugar Support Looks Different for Everyone

Blood glucose dysregulation doesn’t happen the same way for everyone. Three broad, consistent drivers explain most demographic variability:

  • Aging reduces insulin sensitivity and glucose disposal, particularly as sarcopenia and visceral adiposity rise. (1–2,4,7,8)
  • Sex hormones define timing and phenotype of risk, notably around puberty, during pregnancy/post-partum, PCOS, and menopause for women, while male adiposity patterns increase earlier visceral-adiposity risk. (9–12,20–22,29)
  • Contextual and behavioral factors (dietary patterns, stress load, sleep, activity) modulate the decline of age-related glycemic changes and the magnitude of postprandial increases in blood sugar. (1–4,7,8)

These differences are not deterministic, but they are clinically meaningful. Framing clinical screening and intervention around these lifecycle windows allows for preventative and personalized counseling.

Glucose Metabolism Across the Lifespan

Glucose management is typically strongest early in life and becomes less efficient with age. Decline begins when most people are in their 30s and shows up as reduced insulin sensitivity, reduced ability of β-cells to make enough insulin, and diminished skeletal-muscle glucose uptake. Importantly, one's lifestyle mediates the rate of this decline. (1–4,8)

Youth

Children are generally highly insulin-sensitive with efficient postprandial glucose management supporting their rapid growth. (5) Puberty introduces a transient, physiologic increase in insulin resistance and fasting glucose, which is linked to growth-hormone surges and is more pronounced in girls. This typically resolves by late puberty/early adulthood. (6,9)

Clinical relevance: Obesity or inactivity when entering puberty can prevent full recovery of insulin sensitivity, increasing early-onset risk factors. (5–6)

Middle Age

From the mid-20s onward, fasting glucose rises each decade, and T2D prevalence accelerates in the 40s. (5,7) Evidence points less to the natural aging process and more to modifiable factors like increases in visceral fat, declining activity, gradual muscle loss, and higher chronic stress load. (1,2,5,7)

Clinical opportunity: Repeated postprandial hyperglycemia episodes during midlife can accelerate β-cell stress and insulin resistance even before fasting glucose becomes abnormal. (1–4,7,8)

Older Age

After ~60, changes build up to disrupt the body’s post-meal metabolism:

  • Skeletal muscle declines in mass and glucose-uptake efficiency; muscle disposes ~70% of post-meal glucose. (1–2,8)
  • β-cells gradually lose their ability to secrete insulin, limiting compensation for rising insulin resistance. (1,4,8)
  • Visceral adiposity and inflammatory markers increase independent of BMI change. (2,4,8)
  • Microbiome diversity drops, decreasing SCFA production and GLP-1–supportive microbial species. (28,31)

Visceral adiposity focus: Older adults may carry ~200–300% more visceral fat than younger adults at similar body weight which is an important driver of age-related insulin resistance. (13)

Sex-Based Differences in Blood Sugar and Insulin Sensitivity

Sex differences are driven primarily by fat distribution and hormone-regulated insulin action. (9–12)

Males

Men accumulate visceral fat earlier and more centrally, promoting inflammation and insulin resistance. This helps explain earlier impaired fasting glucose and T2D diagnosis at younger ages and lower BMIs than women. (2,10–11,14–15)

Low testosterone and high blood sugar influence each other in both directions: visceral fat suppresses testosterone; low testosterone further promotes fat gain. Approximately one-third of men over 40 or overweight may have low sex-hormone production linked to metabolic dysfunction. (11,16–19)

Meal-time positioning: In male patients with early central fat build up and starch-dense meals, slowing carb digestion during meals can lessen post-meal spikes while body-composition changes start to work. (10–12)

Females

Premenopausal estrogen supports skeletal-muscle glucose uptake, reduces hepatic glucose output, and promotes more hip-and-thigh fat storage, yielding better insulin sensitivity than age-matched men. (10,12) However, women experience discrete transition-linked risk windows:

  • Pregnancy: physiologic insulin resistance rises in late gestation; gestational diabetes develops if β-cells cannot compensate. (10)
  • Post-gestational diabetes: future T2D risk increases ~10×. (29)
  • PCOS: affects ~6–13% of reproductive-age women; IR is a core feature that is responsive to low-glycemic dietary patterns and lifestyle. (11,20–21)
  • Menopause: rapid estrogen decline shifts fat toward visceral storage and elevates IR to male-like or higher levels. (10,22)

Meal-time positioning: Post-partum (after breastfeeding), PCOS phenotypes, and peri-/post-menopausal transitions are clinically appropriate contexts for targeted postprandial support. (10,20–22,29)

Evidence-Based Strategies for Postprandial Control

These interventions show reliable cross-demographic benefit and should be core to lifestyle approaches:

  1. Preserve or increase skeletal muscle.
    Resistance training 2–4×/week preserves insulin sensitivity and mitigates age-related decline in glucose disposal. (1–2,8)

  2. Reduce visceral fat drivers.
    HIIT or brisk walking, sleep optimization, stress reduction, and lowering refined carbohydrate intake reduce visceral fat and inflammation, even without major weight loss. (2,4,8)

  3. Smaller blood sugar spikes after meals.
    Pairing carbohydrates with protein, fiber, and fats slows digestion and reduces peak glycemia, improving outcomes in PCOS and midlife metabolic shifts. (21)

  4. Support gut-microbiome function.
    Prebiotic fibers (legumes, oats, resistant starches, alliums) sustain SCFA-producing species; SCFAs enhance gut barrier integrity, reduce inflammation, and support GLP-1 secretion. (28,31)

  5. Time interventions to defined windows.
    Men: earlier focus during visceral-fat expansion.
    Women: intensified support post-gestational diabetes and through menopause transition. (10,20,22,29)

Targeted Meal-Time Interventions using Premier Glucose Manager with Reducose® + GlucoVantage® Dihydroberberine

Reducose® (Morus alba leaf extract, 5% DNJ)

Reducose® is a proprietary aqueous white mulberry leaf extract standardized to 1-deoxynojirimycin (DNJ). DNJ competitively inhibits intestinal α-glucosidase enzymes, slowing hydrolysis of starches and disaccharides and thereby reducing the rate of glucose entering blood circulation. (32,33)

Clinical outcomes: Trials show significant reductions in postprandial glucose iAUC (up to ~42%) and insulin iAUC (up to ~41%) during sugar challenges. Additionally, GI lowering was found across sucrose, maltose/maltodextrin, and white bread. (34,35) DNJ is rapidly cleared unchanged via the kidneys, and clinical data demonstrate high tolerability comparable to placebo even at high doses. (30)

Clinical application: Best used as a meal-time add-on for people who often get post-meal spikes in midlife or during hormonal transitions (men with belly fat, peri/post-menopause, or after gestational diabetes once breastfeeding ends), especially in diets built around starchy staples. (10,22,29,30,32)

GlucoVantage® Dihydroberberine (DHB)

Berberine is supported by extensive clinical and mechanistic literature for improving fasting glucose, postprandial glucose, insulin resistance, and HbA1c, with parallel benefits in lipid metabolism and cardiometabolic risk. (36–38) Dihydroberberine (DHB) is the reduced, bioactive metabolite of berberine. Compared with standard berberine, GlucoVantage® DHB shows greater levels in the body and lasts longer in people. (40)

Mechanistic relevance for practice: DHB supports insulin sensitivity and glucose disposal through AMPK activation fits well with how the body responds after meals. (39,42)

Why the combination is clinically applicable:
Premium Glucose Manager pairs Reducose® and GlucoVantage® DHB to target two sequential steps in post-meal blood sugar:

  • Reducose® moderates intestinal carbohydrate digestion and glucose entering the bloodstream. (32–35)
  • DHB optimizes downstream glucose handling via insulin-sensitizing and AMPK-mediated pathways. (36–42)

This “influx + utilization” pairing is helpful for patients showing persistent post-meal glucose excursions despite optimal lifestyle choices and especially within recognized lifecycle timeframes. (10,20,22,29–35,36–42)

Suggested use:

Take before carbohydrate-containing meals: DNJ’s competitive inhibition requires taking it with carbs. (32) DHB’s improved absorption and lasting effect make it reliable to use at meals for recurring spikes or predictable food triggers. (41,42)

Safety notes:

Berberine/DHB may interact with select medications and is not recommended in pregnancy/breastfeeding without clinician oversight. Mild GI effects may occur initially, though DHB typically requires lower oral dosing than standard berberine. (36,41, 42)

Key Takeaways

  • Age-related glycemic shifts are expected but can be changed: Muscle preservation, visceral-fat reduction, microbiome support, and postprandial stabilization maintain metabolic resilience. (1–4,8,28,31)
  • Sex differences define timing more than mechanism: Earlier male visceral-fat risk and later female transition risk merit lifecycle-specific screening and messaging. (10–12,20–22,29)
  • Reducose® is mechanistically aligned and clinically validated for reducing postprandial glycemic exposure across different carbohydrate meals. (32–35)
  • GlucoVantage®DHB extends berberine’s clinical utility by improving bioavailability, supporting insulin sensitivity at lower doses. (36–42)
  • The combination provides a practical meal-time tool for repeated spikes during high-risk periods, alongside lifestyle and body-composition care. (10,20,22,29–42)

Blood sugar changes with age are normal but can be improved with muscle development support, less belly fat, gut health, and smaller post-meal spikes. Because men and women tend to face higher risk at different times, screening should match life stage. Reducose® helps lower post-meal rises, and GlucoVantage® DHB makes berberine work better, so together in Premier Glucose Manager they’re an easy meal-time option alongside managed lifestyle care.

References

  1. Chia CW, Egan JM, Ferrucci L. Age-related changes in glucose metabolism, hyperglycemia, and cardiovascular risk. Circ Res. 2018;123(7):886-904. doi:10.1161/CIRCRESAHA.118.312806.
  2. Palmer AK, Jensen MD. Metabolic changes in aging humans: current evidence and therapeutic strategies. J Clin Invest. 2022;132(16):e158451. doi:10.1172/JCI158451.
  3. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. Cell. 2023;186(2):243-278. doi:10.1016/j.cell.2022.11.001.
  4. De Tata V. Age-related impairment of pancreatic beta-cell function: pathophysiological and cellular mechanisms. Front Endocrinol (Lausanne). 2014;5:138. doi:10.3389/fendo.2014.00138.
  5. Hammel MC, Stein R, Kratzsch J, et al. Fasting indices of glucose-insulin metabolism across life span and prediction of glycemic deterioration in children with obesity from new diagnostic cut-offs. Lancet Reg Health Eur. 2023;30:100652. doi:10.1016/j.lanepe.2023.100652.
  6. Kelsey MM, Zeitler PS. Insulin resistance of puberty. Curr Diab Rep. 2016;16(7):64. doi:10.1007/s11892-016-0751-5.
  7. Fazeli PK, Lee H, Steinhauser ML. Aging is a powerful risk factor for type 2 diabetes mellitus independent of body mass index. Gerontology. 2020;66(2):209-210. doi:10.1159/000501745.
  8. Gong Z, Muzumdar RH. Pancreatic function, type 2 diabetes, and metabolism in aging. Int J Endocrinol. 2012;2012:320482. doi:10.1155/2012/320482.
  9. Hoffman RP, Vicini P, Sivitz WI, Cobelli C. Pubertal adolescent male-female differences in insulin sensitivity and glucose effectiveness determined by the one-compartment minimal model. Pediatr Res. 2000;48(3):384-388. doi:10.1203/00006450-200009000-00022.
  10. Kautzky-Willer A, Leutner M, Harreiter J. Sex differences in type 2 diabetes. Diabetologia. 2023;66(6):986-1002. doi:10.1007/s00125-023-05891-x.
  11. Ciarambino T, Crispino P, Guarisco G, Giordano M. Gender differences in insulin resistance: new knowledge and perspectives. Curr Issues Mol Biol. 2023;45(10):7845-7861. doi:10.3390/cimb45100496.
  12. Rattarasarn C, Leelawattana R, Soonthornpun S. Skeletal muscle contribution to sex differences in OGTT. Metabolism. 2010;59(2):172-176. doi:10.1016/j.metabol.2009.06.029.
  13. Dobre MZ, Virgolici B, Timnea O. Key roles of brown, subcutaneous, and visceral adipose tissues in obesity and insulin resistance. Curr Issues Mol Biol. 2025;47(5):343. doi:10.3390/cimb47050343.
  14. Clausen JO, Borch-Johnsen K, Ibsen H, et al. Insulin sensitivity index, acute insulin response, and glucose effectiveness in a population-based sample of 380 young healthy Caucasians. J Clin Invest. 1996;98(5):1195-1209. doi:10.1172/JCI118903.
  15. Liu N, Feng Y, Ma X, Ma F. Prevalence of testosterone deficiency among US adult males. Aging Male. 2022;25(1):278-280. doi:10.1080/13685538.2022.2130236.
  16. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2008;60(7):762-769. doi:10.1111/j.1742-1241.2006.00992.x.
  17. Zitzmann M. Testosterone deficiency, insulin resistance, and metabolic syndrome. Nat Rev Endocrinol. 2009;5(12):673-681. doi:10.1038/nrendo.2009.212.
  18. World Health Organization. Polycystic ovary syndrome (PCOS) fact sheet. Updated February 7, 2025.
  19. Gautam R, Maan P, Jyoti A, et al. The role of lifestyle interventions in PCOS management: a systematic review. Nutrients. 2025;17(2):310. doi:10.3390/nu17020310.
  20. Davis SR, Pinkerton J, Santoro N, Simoncini T. Menopause—biology, consequences, supportive care, and therapeutic options. Cell. 2023;186(19):4038-4058. doi:10.1016/j.cell.2023.08.016.
  21. Do Vale Moreira NC, Ceriello A, Basit A, et al. Race/ethnicity and challenges for optimal insulin therapy. Diabetes Res Clin Pract. 2021;175:108823. doi:10.1016/j.diabres.2021.108823.
  22. Yaghootkar H, Whitcher B, Bell JD, Thomas EL. Ethnic differences in adiposity and diabetes risk—insights from genetic studies. J Intern Med. 2020;288(3):271-283. doi:10.1111/joim.13082.
  23. Lewis C, Cohen PR, Bahl D, et al. Race and ethnic categories: a brief review of global terms and nomenclature. Cureus. 2023. doi:10.7759/cureus.41253.
  24. Golden SH, Yajnik C, Phatak S, Hanson RL, Knowler WC. Racial/ethnic differences in the burden of type 2 diabetes over the life course. Diabetologia. 2019;62(10):1751-1760. doi:10.1007/s00125-019-4968-0.
  25. Sadiya A, Jakapure V, Kumar V. Ethnic variability in glucose and insulin response to rice among healthy overweight adults: a randomized cross-over study. Diabetes Metab Syndr Obes. 2023;16:993-1002. doi:10.2147/DMSO.S404212.
  26. Ragonnaud E, Biragyn A. Gut microbiota as key controllers of healthy aging. Immunity Ageing. 2021;18(1):2. doi:10.1186/s12979-020-00213-w.
  27. Vounzoulaki E, Khunti K, Abner SC, et al. Progression to type 2 diabetes in women with prior gestational diabetes. BMJ. 2020;369:m1361. doi:10.1136/bmj.m1361.
  28. Zeng Y, Wu Y, Zhang Q, Xiao X. Crosstalk between glucagon-like peptide-1 and gut microbiota in metabolic diseases. mBio. 2024;15(1):e02032-23. doi:10.1128/mbio.02032-23.
  29. Centers for Disease Control and Prevention. U.S. Diabetes Surveillance System. Accessed 2025.
  30. Gheldof N, Francey C, Rytz A, et al. Effect of different nutritional supplements on glucose response of complete meals in two crossover studies. Nutrients. 2022;14(13):2674.
  31. Han H, Yi B, Zhong R, Wang M, Zhang S, Ma J, Yin Y, Yin J, Chen L, Zhang H. From gut microbiota to host appetite: gut microbiota-derived metabolites as key regulators. Microbiome. 2021 Jul 20;9(1):162.
  32. Wang R, Li Y, Mu W, et al. Mulberry leaf extract reduces the glycemic indexes of four common dietary carbohydrates. Medicine (Baltimore). 2018;97(34):e11996.
  33. Thondre PS, Lightowler H, Ahlstrom L, Gallagher A. Mulberry leaf extract improves glycaemic and insulaemic response to sucrose in healthy subjects. Nutr Metab (Lond). 2021;18(1):41.
  34. Ding F, Wang Q, Xie C, et al. Mulberry leaf extract reduces the glycemic index of white bread. PLoS One. 2023;18(8):e0288911.
  35. Lown M, Fuller R, Lightowler H, et al. Mulberry-extract improves glucose tolerance and decreases insulin concentrations in normoglycaemic adults. PLoS One. 2017;12(2):e0172239.
  36. Nazari A, Ghotbabadi ZR, Kazemi KS, et al. Effect of berberine supplementation on glycemic control and inflammatory biomarkers: umbrella meta-analysis of RCTs. Clin Ther. 2024;46(2):e64-e72. doi:10.1016/j.clinthera.2023.10.019.
  37. Ji L, Wang L, Wei G, et al. Berberine for type 2 diabetes outcomes: systematic review and meta-analysis of RCTs. Front Pharmacol. 2024. doi:10.3389/fphar.2024.1455534.
  38. Li Y, et al. Berberine ursodeoxycholate for type 2 diabetes treatment: randomized clinical trial. JAMA Netw Open. 2024;7:e2462185. doi:10.1001/jamanetworkopen.2024.62185.
  39. Addressing the preventive and therapeutic perspective of berberine against diabetes and metabolic dysfunction. Heliyon. 2023.
  40. NNB Nutrition. GlucoVantage® (dihydroberberine) ingredient overview. Accessed December 9, 2025.
  41. DiNicolantonio JJ, Bhutani J, O’Keefe JH. Absorption kinetics of berberine and dihydroberberine and their clinical implications. Nutrients. 2022;14(1):124. doi:10.3390/nu14010124.
  42. NNB Nutrition. What is GlucoVantage®? Bioavailability and metabolic actions of DHB. 2025.

_____________________________________________________________________
 

Lisa Offringa, PhD, currently serves as Phynova’s scientific affairs manager, where she supports customers and communicates the scientific evidence supporting the health benefits of its ingredients. During her career as a medical and nutritional ethnobotanist, she combined science with a strategic business acumen to deliver health solutions rooted in plants. She had previous roles in R&D, product development, and scientific affairs at companies like Brightseed Bio, Better Health VMS, and Magdalena Biosciences. Offringa earned her PhD in plant sciences from the New York Botanical Garden and CUNY, and completed her postdoctoral work at Stanford University School of Medicine and Nutrition at UC Berkeley.